LearnGlossaryMarketStocksSuperinvestorsSign in

KPTI

Karyopharm Therapeutics Inc.

Healthcare · $38M market cap

Verdict

We can't put a fair value on KPTI right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-31.2% a year✗
Sales growth22.1% a year✓
Free cash flow growth—?
Return on invested capital-54.8%✗

Follow KPTI

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 1 sale worth $38. Why purchases matter

Sales

Abate Kristin

Chief Accounting Officer · 2026-09-01

Sold

$38

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE)…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works